Pfizer has announced that it will stop making and selling Exubera, its inhaled insulin, 15 months after it went on sale.
"Despite all our efforts, Exubera has not gained the acceptance of patients and doctors we had hoped for, so we are ending our investment in it," said chief executive Jeff Kindler. Few doctors prescribed it because of concerns about its long-term effects on lung function and its high price.
0
Like
0
Love
0
Angry
0
Dislike
0
